LexBio Overview
- Year Founded
-
2021
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
- Investors
-
4
LexBio General Information
Description
Developer of a drug discovery platform designed to accelerate the development of innovative medicines. The company's platform utilizes deep learning algorithms and professional databases to perform target screening, molecular optimization, and candidate compound generation, enabling biopharmaceutical companies to identify differentiated medicines and reduce experimental costs.
Contact Information
Website
www.m.langruibio.comCorporate Office
- Room 409, 4th Floor, Building C17, Phase I Biomedical Industrial Park
- Number 218 Xinghu Street, Suzhou Industrial Park, Suzhou Area China Pilot Free Trade Zone
- Suzhou, Jiangsu 215000
- China
Corporate Office
- Room 409, 4th Floor, Building C17, Phase I Biomedical Industrial Park
- Number 218 Xinghu Street, Suzhou Industrial Park, Suzhou Area China Pilot Free Trade Zone
- Suzhou, Jiangsu 215000
- China
LexBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | 03-Sep-2026 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 10-Oct-2023 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 28-Mar-2023 | Completed | Generating Revenue | |||
| 1. Seed Round | 19-Apr-2021 | Completed | Generating Revenue |
LexBio Patents
LexBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026158438-A1 | Pentacyclic derivative, and preparation method therefor and use thereof | Pending | 24-Jan-2025 | ||
| AU-2025250225-A1 | A pyrrolo [2, 3-b] pyridine derivative, and preparation method therefor and use thereof | Pending | 01-Apr-2024 | ||
| WO-2025209278-A1 | A pyrrolo [2, 3-b] pyridine derivative, and preparation method therefor and use thereof | Pending | 01-Apr-2024 | ||
| US-20260028352-A1 | Macrocyclic imidazo [1,2-b] pyridazine derivative, preparation method therefor, and use thereof | Pending | 07-Sep-2022 | ||
| AU-2023339247-A1 | Macrocyclic imidazo[1,2-b]pyridazine derivative, preparation method therefor, and use thereof | Active | 07-Sep-2022 | C07D498/22 |
LexBio Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Leader Venture Capital | Growth/Expansion | Minority | ||
| Ascentage Pharma | Corporation | Minority | ||
| Grains Valley Venture Capital | Venture Capital | Minority | ||
| Suzhou Oriza Holdings Corporation | Asset Manager | Minority |
LexBio FAQs
-
When was LexBio founded?
LexBio was founded in 2021.
-
Where is LexBio headquartered?
LexBio is headquartered in Suzhou, China.
-
What industry is LexBio in?
LexBio’s primary industry is Drug Discovery.
-
Is LexBio a private or public company?
LexBio is a Private company.
-
What is LexBio’s current revenue?
The current revenue for LexBio is .
-
Who are LexBio’s investors?
Leader Venture Capital, Ascentage Pharma, Grains Valley Venture Capital, and Suzhou Oriza Holdings Corporation have invested in LexBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process